Similar articles

• Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool.

  Di Chiro G. Di Chiro G. Invest Radiol. 1987 May;22(5):360-71. doi: 10.1097/00004424-198705000-00002. Invest Radiol. 1987. PMID: 3496318 No abstract available.
• [Tomographic mapping of rate constants of [F-18] FDG model].

  Sasaki H, Kanno I, Miura S, Murakami M, Takahashi K, Shishido F, Uemura K. Sasaki H, et al. Kaku Igaku. 1985 Jan;22(1):81-4. Kaku Igaku. 1985. PMID: 3873558 Japanese. No abstract available.
• [A new method for analyzing the local cerebral metabolic rate of glucose using an 18FDG positron CT-image].

  Endo M, Shishido F, Fukuda N, Matsumoto T, Iinuma TA, Tateno Y, Yamasaki T, Takashima T, Tamachi S. Endo M, et al. Kaku Igaku. 1983 Jun;20(5):699-702. Kaku Igaku. 1983. PMID: 6604830 Japanese. No abstract available.
• 2-Deoxy-2-[18F]fluoro-D-glucose for metabolic studies: current status.

  Fowler JS, Wolf AP. Fowler JS, et al. Int J Rad Appl Instrum A. 1986;37(8):663-8. doi: 10.1016/0883-2889(86)90259-5. Int J Rad Appl Instrum A. 1986. PMID: 3021667 Review. No abstract available.
• Assessment: positron emission tomography. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  [No authors listed] [No authors listed] Neurology. 1991 Feb;41(2 ( Pt 1)):163-7. Neurology. 1991. PMID: 1992357 Review. No abstract available.